限制性输血在老年骨科手术患者中应用的临床研究

注册号:

Registration number:

ChiCTR-TRC-10000822 

最近更新日期:

Date of Last Refreshed on:

2015-06-07 14:05:15 

注册时间:

Date of Registration:

2010-04-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

限制性输血在老年骨科手术患者中应用的临床研究

Public title:

clinical research of restrictive transfusion in elderly patients undergoing orthopedic surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

限制性输血在老年骨科手术患者中应用的临床研究

Scientific title:

clinical research of restrictive transfusion in elderly patients undergoing orthopedic surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

武庆平 

研究负责人:

武庆平 

Applicant:

Qingping Wu 

Study leader:

Qingping Wu 

申请注册联系人电话:

Applicant telephone:

+86 13971605283

研究负责人电话:

Study leader's
telephone:

+86 13971605283

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wu_qingping1968@yahoo.com.cn

研究负责人电子邮件:

Study leader's E-mail:

wu_qingping1968@yahoo.com.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

武汉市解放大道1277号

研究负责人通讯地址:

武汉市解放大道1277号

Applicant address:

No. 1277, Jiefang Road, Jianghan District, Wuhan, Hubei, China

Study leader's address:

No. 1277, Jiefang Road, Jianghan District, Wuhan, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

430022

研究负责人邮政编码:

Study leader's postcode:

430022

申请人所在单位:

华中科技大学同济医学院附属协和医院麻醉科

Applicant's institution:

Department of Anaesthesiology, Union Hospital, Wuhan, Hubei, China

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

华中科技大学同济医院附属协和医院麻醉科

Primary sponsor:

Department of Anaesthesiology, Union Hospital, Wuhan, Hubei, China

研究实施负责(组长)单位地址:

武汉市解放大道1277号

Primary sponsor's address:

No. 1277, Jiefang Road, Jianghan District, Wuhan, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

Ch'ina

Province:

Beijing

City:

单位(医院):

中国人民共和国卫生部

具体地址:

中国人民共和国卫生部

Institution
hospital:

Ministry of Health, China.

Address:

Ministry of Health, China.

经费或物资来源:

中华人民共和国卫生部专项财务司

Source(s) of funding:

specific finance department of Ministry of Health, China.

研究疾病:

老年骨科手术患者  

Target disease:

elderly patients undergoing orthopedic surgery

研究疾病代码:

S22,S32,S72-S93;

Target disease code:

S22,S32,S72-S93;

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本课题将老年骨科手术患者作为调查和研究对象,采取术中实时监测血红蛋白和红细胞压积的技术,应用限制性输血策略,取得第一手的临床研究资料,为制定更为细致明确的手术用血指南提供客观依据。同时,结合并针对研究结果开展限制性输血的血液保护技术研究,推广血液保护意识。  

Objectives of Study:

This issue takes elderly patients undergoing orthopedic surgery as research subjects. With application of restrictive blood transfusion policy and intraoperative real-time monitoring of hematocrit , the first-hand clinical research data will be obtained and used to develop more detaild surgical transfusion guidelines. Moreover, with combination of the blood conservation technologies in the issue, we aim to promote the awareness of blood conservation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

Hct<0.35,Plt<50g/l或功能异常;
凝血功能异常;
异常血小板消耗性疾病(如脾亢);
严重功能脏器(心、肝、肺和肾)疾病伴感染性发热或菌血症;
未纠正的休克;
造血系统疾病;

Exclusion criteria:

Hct <0.35, Plt <50g / l or abnormal function;
Coagulopathy;
Abnormal platelet depletion disease (eg, splenomegaly);
Severe functional organs (heart, liver, lung and kidney) disease; With infection and fever or bacteremia;
With hematopoietic system diseases;
Not voluntary or refuse to coordinate.

研究实施时间:

Study execute time:

From 2010-05-01 00:00:00 To 2011-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2010-05-01 00:00:00 To 2011-03-01 00:00:00

干预措施:

Interventions:

组别:

限制性输血组1

样本量:

30

Group:

group 1

Sample size:

干预措施:

Hct<0.25时输血,以维持Hct 0.25—0.30

干预措施代码:

Intervention:

transfusion if Hct<0.25 and maintain Hct 0.25-0.30

Intervention code:

组别:

限制性输血组2

样本量:

30

Group:

group 2

Sample size:

干预措施:

Hct<0.25时输血,Hct到达0.30后继续输血

干预措施代码:

Intervention:

transfusion if Hct<0.25 and continue transfusion even if Hct >=0.30

Intervention code:

组别:

限制性输血组3

样本量:

30

Group:

group 3

Sample size:

干预措施:

Hct未降至0.30以下,输血组

干预措施代码:

Intervention:

Hct never decrease to 0.30, transfusion

Intervention code:

组别:

限制性输血组4

样本量:

30

Group:

group 4

Sample size:

干预措施:

Hct未降至0.30以下,不输血组

干预措施代码:

Intervention:

Hct never decrease to 0.30, no transfusion

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

Hct<0.35时输血,以维持Hct >0.35

干预措施代码:

Intervention:

Hct never decrease to 0.30, no transfusion

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

华中科技大学同济医学院附属协和医院麻醉科 

单位级别:

三级甲等医院 

Institution
hospital:

Wuhan City, Hubei Province

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

Hb,CVP,BP(MAP),SP02, ECG,气道压,补液量,呼末二氧化碳等

指标类型:

主要指标

Outcome:

Hb, CVP, BP(MAP), SP02, ECG, Airway pressure, infusion volume, ETCO2

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恢复(术后24h引流量,伤口愈合时间、等级,感染率,下床时间,出院时间

指标类型:

次要指标

Outcome:

recovery (24h drainage, heal of the incision, infection, hospital stay length)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

认知功能,术后并发症(凝血功能紊乱,酸碱平衡电解质紊乱等)

指标类型:

副作用指标

Outcome:

cognitive function, complications (coagulation disorders, electrolyts disorders)

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

数据分析人员 是 研究人员 否 研究对象 是

Blinding:

researcher: not statisticians: blinding subjects: blinding

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

华中科技大学同济医学院附属协和医院麻醉科

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Department of Anaesthesiology, Union Hospital, Wuhan, Hubei, China

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

华中科技大学同济医学院附属协和医院麻醉科

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Department of Anaesthesiology, Union Hospital, Wuhan, Hubei, China

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-06-07 14:05:15